Berotralstat Uses, Dosage, Side Effects and Interactions
Orladeyo
Orladeyo was approved by the FDA in December 2020. No generic is listed as oral pellets and capsules.
Berotralstat is a once-daily oral medicine that helps prevent attacks of hereditary angioedema (HAE) in adults and children 2 years and older. It does not treat attacks once they start.
Quick links
Ask Anything About BerotralstatType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Berotralstat in Short
- Drug class Plasma Kallikrein Inhibitor How the FDA classifies it
What it treatsBerotralstat (brand name Orladeyo) is used to prevent attacks of hereditary angioedema (HAE). HAE is a condition that causes episodes of swelling and pain. It is approved for adults and children 2 years of age and older. It is not for treating an attack that is already happening.
- How you get it Prescription only
- Comes asOral pellets and capsuleAvailable strengths
Oral pellets (by mouth)
- 72 mg
- 96 mg
- 108 mg
- 132 mg
- 150 mg
Capsule (by mouth)
- 110 mg
See forms and strengths+ 1 more strengthShow fewer strengths
Capsule (by mouth)
- 150 mg
- Important safety informationWarnings and precautions Read the warnings and precautions for your exact product.
- What Medicaid pays
- Orladeyo (brand)$1,584.29 to $1,642.69 a capsule
- Oral pellets: no national price found
- Generic launchOctober 2035 Our estimate for the first generic of Orladeyo
The Pharmacist’s Take
Berotralstat (Orladeyo) prevents attacks of hereditary angioedema (HAE) by blocking plasma kallikrein, which keeps bradykinin, the substance that makes blood vessels leak and swell, in check; it was the first once-daily option by mouth for HAE prevention, is still fairly new, and is not available as a generic. Most people tolerate it well, and the side effects they notice are mostly stomach-related (belly pain, diarrhea, vomiting, heartburn), often early on. The thing to respect is the dose, because it will not stop an attack already underway and extra doses can lengthen the QTc interval, a measure of the heart's electrical cycle.
Key Takeaways From the HelloPharmacist Team
- Take it once a day with food, as a capsule for ages 12 and up or as weight-based oral pellets for younger children.
- Keep your rescue medicine for acute attacks with you and follow your HAE action plan, since berotralstat only lowers how often attacks happen.
- Never double up to make up for a missed dose, and get medical help if you take more than your prescribed daily amount.
- Run every new prescription, over-the-counter or herbal product past your pharmacist, because berotralstat raises levels of many medicines and some drugs weaken it.
Patient Information Guide for Berotralstat
What It’s Used For
Berotralstat is used to prevent attacks of hereditary angioedema (HAE).
- Orladeyo is approved to prevent HAE attacks in adults and children 2 years and older.
- Orladeyo capsules are for those 12 and older.
- Orladeyo oral pellets are for children 2 to under 12 years.
- It is not for treating acute HAE attacks.
How It Works
Berotralstat is a plasma kallikrein inhibitor. It blocks plasma kallikrein, a protein that helps make bradykinin. Bradykinin widens blood vessels and makes them leaky, causing the swelling and pain of HAE.
In people with HAE due to C1-inhibitor deficiency or dysfunction, plasma kallikrein is not properly regulated. Berotralstat reduces its activity to help control extra bradykinin.
Drug Class
Drug Class
- Plasma Kallikrein Inhibitor
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)- Plasma Kallikrein Inhibitor
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)- Cytochrome P450 2D6 Inhibitors
- Cytochrome P450 3A4 Inhibitors
- Kallikrein Inhibitors
- P-Glycoprotein Inhibitors
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)None listed for Berotralstat in the FDA’s index.
From our Patient Information GuideBerotralstat is a plasma kallikrein inhibitor. It blocks plasma kallikrein, a protein that helps make bradykinin. Bradykinin widens blood vessels and makes them leaky, causing the swelling and pain of HAE. Read How Berotralstat Works
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)None listed for Berotralstat in the FDA’s index.
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- Drugs used in hereditary angioedema
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Dosage
Orladeyo is taken by mouth once a day with food.
- Adults and children 12 and older take capsules.
- Children 2 to under 12 take oral pellets, dosed by body weight.
- Some people with liver problems or persistent stomach side effects may be given a lower capsule dose.
Follow your prescriber's directions and the label. Do not take extra doses.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Preventing attacks of hereditary angioedema (HAE)
Adults and children 12 years old and older Usual dose 150 mg once a day
- 150 mg orally once daily with food
Good to know
Higher than the prescribed once-daily dose is not recommended
Adults and children 12 and older · 110 mg Usual dose 110 mg once a day
- 110 mg taken orally once daily with food
Good to know
Mild hepatic impairment (Child-Pugh Class A): no dosage modification
Adults and children 12 and older · Persistent GI adverse reactions Usual dose 110 mg once a day
- Consider a lower dosage of 110 mg once daily with food
Good to know
For ages 2 to less than 12 years, consider risks and benefits of continuing treatment
Children 2 to less than 12 years old, 12 kg to less than 24 kg Usual dose 72 mg once a day
Good to know
Take with food; a meal just before or after dosing
Children 2 to less than 12 years old, 24 kg to less than 32 kg Usual dose 96 mg once a day
Good to know
Take with food; a meal just before or after dosing
Children 2 to less than 12 years old, 32 kg to less than 40 kg Usual dose 108 mg once a day
Good to know
Take with food; a meal just before or after dosing
Children 2 to less than 12 years old, 40 kg or greater Usual dose 132 mg once a day
Good to know
Take with food; a meal just before or after dosing
Side Effects
Stomach-related effects are the most common.
Common side effects
- Stomach (abdominal) pain
- Vomiting
- Diarrhea
- Back pain
- Heartburn or acid reflux (gastroesophageal reflux disease)
- Headache
- Fatigue
- Gas (flatulence)
When to get medical help
- Call your doctor if stomach upset, vomiting or diarrhea keeps going. A lower dose may be an option for some people.
- Get medical help if you took more than your prescribed daily dose. Higher doses can affect the heart's electrical rhythm (QTc prolongation).
- Tell your doctor about a new skin rash. Rash was rare in studies and went away, even in people who kept taking the medicine.
- Do not use it to treat an attack in progress. Follow your HAE action plan and call your doctor.
Stomach effects usually appeared early, became less frequent over time and typically went away on their own. Nausea has also been reported after approval. Contact your doctor if symptoms persist or you develop a rash.
Warnings and Precautions
The biggest warning is QTc interval prolongation (a change in the heart's electrical rhythm) at higher-than-recommended doses. Do not take extra doses or more than prescribed.
Orladeyo should not be used to treat acute HAE attacks. In studies, one person stopped treatment because of elevated liver enzymes found on lab tests.
Interactions
Orladeyo can interact with several types of medicines.
- P-gp inducers: can lower Orladeyo levels and make it less effective, so avoid them.
- CYP2D6 or CYP3A4 substrates: Orladeyo can raise their levels.
- P-gp substrates: Orladeyo can raise their levels.
- Desogestrel: levels of its active form can rise.
Interactions Listed in the FDA-Approved Label
From the Berotralstat prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
P-gp inducersWhat happensP-gp inducers may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO.What to doAvoid concomitant use.
-
CYP2D6 and CYP3A4 substratesWhat happensORLADEYO 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4 and can increase exposure to these substrates, raising the risk of their adverse reactions.What to doWhere minimal increases may lead to serious adverse reactions, closely monitor or modify the substrate dosage.
-
DesogestrelWhat happensORLADEYO increases exposure to etonogestrel, the active metabolite of desogestrel, and may increase the risk of desogestrel-associated adverse reactions.What to doConsider the benefits and risks when using together.
-
P-gp substratesWhat happensORLADEYO at 2-times the maximum recommended dose of 150 mg is a P-gp inhibitor and can increase exposure of P-gp substrates, raising the risk of their adverse reactions.What to doHigher-than-recommended dosages are not recommended; where minimal increases may lead to serious adverse reactions, closely monitor or modify the substrate dosage.
Read the label’s full interactions text
7 DRUG INTERACTIONS P-gp inducers: Avoid use with ORLADEYO. CYP2D6, CYP3A4 or P-gp Substrates: When used concomitantly with ORLADEYO, closely monitor or modify the dosage of the substrates where minimal increases in concentration may lead to serious adverse reactions. 7.1 Effect of Other Drugs on ORLADEYO P-gp Inducers Berotralstat is a substrate of P-gp and BCRP. P-gp inducers may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO. Avoid concomitant use of P-gp inducers with ORLADEYO. 7.2 Effect of ORLADEYO on Other Drugs CYP2D6 and CYP3A4 Substrates ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. Concomitant use of ORLADEYO with CYP2D6 or CYP3A4 substrates can increase exposure of the CYP2D6 or CYP3A4 substrates and may increase the risk of adverse reactions associated with the substrates. If ORLADEYO is concomitantly used with CYP2D6 or CYP3A4 substrates where minimal increases in the concentration of the substrates may lead to serious adverse reactions, closely monitor or modify the dosage of the CYP2D6 or CYP3A4 substrate. Refer to the Prescribing Information of the CYP2D6 or CYP3A4 substrate. Desogestrel Concomitant use of ORLADEYO with desogestrel increases exposure to etonogestrel, the active metabolite of desogestrel, and may increase the risk of desogestrel-associated adverse reactions. Consider the benefits and risks when using ORLADEYO concomitantly with desogestrel. P-gp Substrates ORLADEYO at 2-times the maximum recommended dose of 150 mg is a P-gp inhibitor and can increase exposure of P-gp substrates, leading to increased risk of adverse reactions associated with the substrates. Higher-than-recommended dosages of ORLADEYO are not recommended.
Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- No contraindications are listed.
- Liver impairment: moderate or severe may need a lower capsule dose; children 2 to under 12 should avoid it.
- Kidney impairment: children 2 to under 12 with severe impairment should avoid it. It is not recommended in end-stage renal disease.
- Pregnancy: data are insufficient to know the risks.
- Breastfeeding: not known whether it passes into milk.
- Not established under 2 years of age.
- Older adults: no overall differences were seen.
Half-Life and How Your Body Processes It
After a dose, levels peak in about 5 hours when taken with food. Food did not meaningfully change how much drug was absorbed, but it delayed the peak. Capsules and pellets gave no clinically significant difference in exposure in adults. It reaches steady state in about 6 to 12 days. Its half-life is about 93 hours. It is broken down by CYP2D6 and CYP3A4 and mostly leaves the body in feces.
Storage
Store at 20°C to 25°C (68°F to 77°F).
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Berotralstat: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Berotralstat — the kind of thing our pharmacy team would talk through with you at the counter.
What is berotralstat used for?
How do I take berotralstat?
What if I take more than my prescribed dose of berotralstat?
What side effects should I expect?
Can I take other medicines with berotralstat?
Is berotralstat safe in pregnancy or while breastfeeding?
Is berotralstat available over the counter?
When was berotralstat first available?
What is the brand name of berotralstat?
What is the generic name of Orladeyo?
What drug class is berotralstat?
What strengths does berotralstat come in?
How much does berotralstat cost?
Is there a berotralstat shortage?
Where can I read the berotralstat prescribing information (package insert)?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Berotralstat
Skip the scrolling. Ask in your own words and get an answer from Berotralstat’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Berotralstat’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Berotralstat on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, as soon as they can.Berotralstat Forms and Strengths (How It Comes)
Berotralstat comes in 2 dose forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Berotralstat inactive ingredients by manufacturer.
Oral pellets
How this form is used
- Orladeyo oral pellets are used to prevent HAE attacks in children 2 to under 12 years, with dosing based on body weight.
- Orladeyo pellets: pour a packet directly into the mouth and swallow right away with water or milk, or sprinkle over about a tablespoon of soft, non-acidic food.
- Orladeyo pellets should not be chewed or crushed, which causes a bitter taste.
- Orladeyo pellets: avoid acidic foods such as yogurt and applesauce. Throw away pellets not eaten within 10 minutes of sprinkling.
- Orladeyo pellets: have a meal just before or after the dose.
Capsule
How this form is used
- Orladeyo capsules are used to prevent HAE attacks in adults and children 12 years and older.
- Orladeyo capsules are taken by mouth once daily with food.
- Orladeyo capsules are the form used if a lower dose is needed, such as for moderate or severe liver impairment or ongoing stomach side effects in people 12 and older.
Berotralstat on the U.S. Market: Products, Makers and Brands
How Berotralstat appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 7 Berotralstat product records with the FDA, mostly as oral pellets, capsule; the earliest marketing or approval year on record is 2018. The one brand name in the directory today is Orladeyo; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (4) · Unfinished capsule (2) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.
How Widely Berotralstat Is Used (Medicaid Data)
How many Berotralstat prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Berotralstat prescribed? Of the 1,682 medications we measure, Berotralstat ranks #1,332 by Medicaid prescriptions — more than 21% of them.
Utilization by Berotralstat product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
berotralstat 150 MG Oral Capsule Most dispensed
1 of 3 listed NDCs had Medicaid claims. RxNorm 2467565
berotralstat 110 MG Oral Capsule
1 of 2 listed NDCs had Medicaid claims. RxNorm 2467573
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 2 of the 5 listed Berotralstat NDCs had Medicaid claims.
Compare Berotralstat Products
A representative set of FDA-listed product records for Berotralstat — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Capsule | ||||
| 110 mg | Oral | BioCryst Pharmaceuticals Inc. | NDA | View NDC → |
| 150 mg | Oral | BioCryst Pharmaceuticals Inc. | NDA | View NDC → |
| 💊Oral pellets | ||||
| 72 mg | Oral | BioCryst Pharmaceuticals Inc. | NDA | View NDC → |
| 96 mg | Oral | BioCryst Pharmaceuticals Inc. | NDA | View NDC → |
| 108 mg | Oral | BioCryst Pharmaceuticals Inc. | NDA | View NDC → |
| 132 mg | Oral | BioCryst Pharmaceuticals Inc. | NDA | View NDC → |
| 150 mg | Oral | BioCryst Pharmaceuticals Inc. | NDA | View NDC → |
Showing 7 of 7 products — FDA National Drug Code Directory. See every product, package size and price: browse all 7 Berotralstat NDCs →
Berotralstat Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Berotralstat — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Berotralstat in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Berotralstat FDA Approval History
How Berotralstat went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Berotralstat Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Berotralstat recalls since July 2021.
✅No Berotralstat recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Berotralstat in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 2
- Strengths
- 6
- Forms in current FDA listings
- 2 of 2
RxCUI 2467540 RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Berotralstat Supply and Shortage Status
Whether Berotralstat is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
What Medicaid Pays for Berotralstat
CMS’s weekly pharmacy survey (NADAC) has no price for Berotralstat, so here is what state Medicaid programs paid for it over the four quarters through Q1 2026, before rebates. It is not your price at the counter.
No price was found for Berotralstat oral pellets, so the prices below are for the capsules only.
| Form | Strength | Version | What Medicaid paid | |
|---|---|---|---|---|
| Capsule · Oral | 110 mg | Orladeyo (brand) | $1,642.69 per capsule | NDC details & Medicaid use |
| Capsule · Oral | 150 mg | Orladeyo (brand) | $1,584.29 per capsule | NDC details & Medicaid use |
Source: CMS State Drug Utilization Data, total paid divided by units paid for across every state, for each strength’s packages.
Berotralstat Brand Names
Berotralstat has one brand name on record: Orladeyo. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Berotralstat: Manufacturers and Labelers
One company lists Berotralstat products with the FDA. By number of product records, the largest are BioCryst Pharmaceuticals, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Berotralstat Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. BioCryst Pharmaceuticals Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →